HC Wainwright reissued their buy rating on shares of CervoMed (NASDAQ:CRVO – Free Report) in a research note released on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for CervoMed’s Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($2.32) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.90) EPS.
Other analysts have also recently issued research reports about the company. D. Boral Capital restated a “buy” rating and set a $31.00 target price on shares of CervoMed in a report on Wednesday, April 22nd. Roth Capital set a $9.00 target price on shares of CervoMed in a research report on Monday, May 18th. Chardan Capital upgraded shares of CervoMed to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, Weiss Ratings lowered shares of CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CervoMed presently has an average rating of “Moderate Buy” and a consensus price target of $21.50.
Get Our Latest Report on CervoMed
CervoMed Trading Down 6.8%
CervoMed (NASDAQ:CRVO – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.22. CervoMed had a negative return on equity of 156.02% and a negative net margin of 672.80%. On average, analysts predict that CervoMed will post -2.4 earnings per share for the current year.
Insider Activity
In related news, Director Joshua S. Boger bought 955,414 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $3.14 per share, for a total transaction of $2,999,999.96. Following the transaction, the director owned 1,795,865 shares in the company, valued at $5,639,016.10. The trade was a 113.68% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 35.80% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers grew its position in CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after acquiring an additional 1,526 shares during the last quarter. Marshall Wace LLP acquired a new stake in CervoMed in the second quarter valued at $76,000. XTX Topco Ltd bought a new position in CervoMed during the 4th quarter worth $81,000. Jane Street Group LLC bought a new position in CervoMed during the 4th quarter worth $88,000. Finally, Dimensional Fund Advisors LP acquired a new position in CervoMed during the 4th quarter worth about $110,000. Institutional investors own 25.15% of the company’s stock.
More CervoMed News
Here are the key news stories impacting CervoMed this week:
- Positive Sentiment: HC Wainwright raised multiple earnings forecasts and reaffirmed its Buy rating. The firm reduced its projected loss for FY2026 to $2.32 per share from $2.70, FY2027 to $1.90 from $1.99, Q3 2026 to $0.48 from $0.60, and Q4 2026 to $0.48 from $0.59. It also improved its Q1 and Q2 2027 loss estimates to $0.46 and $0.41 per share, respectively. HC Wainwright Reaffirms Buy Rating for CervoMed
- Positive Sentiment: Brookline Capital Markets also sharply improved its loss forecasts. The firm lowered its FY2026 projected loss to $2.97 per share from $4.34, while reducing its Q3 and Q4 2026 loss estimates to $0.73 and $0.75 per share from $1.04 and $1.55, respectively. These revisions indicate expectations for better-than-previously-anticipated financial performance.
- Neutral Sentiment: The estimate changes still imply substantial ongoing losses. HC Wainwright’s forecasts remain negative for every listed quarter, and the consensus estimate for CervoMed’s current fiscal year is a $2.50-per-share loss. Investors may therefore view the revisions as incremental rather than evidence of near-term profitability.
- Negative Sentiment: Shares have decreased even with the improved outlook. CervoMed remains a small, loss-making biotechnology company, and its stock is trading below both its 50-day and 200-day moving averages. Without new clinical, regulatory, financing, or commercialization news, analyst estimate changes alone may not be enough to overcome concerns about cash needs and execution risk.
About CervoMed
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.
Read More
- Five stocks we like better than CervoMed
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
